In the CheckMate-227 study, the 5-year overall survival rate for patients with advanced NSCLC with PD-L1 ≥1% was 24% when treated with the nivolumab-ipilimumab combination, as opposed to 14% for those receiving chemotherapy alone. The gene discussed is CD274; the disease is non-small cell lung carcinoma.